Adalvo and Sandoz expands access to a new GLP-1 treatment option in one of the world’s largest and fastest-growing markets
- Brazil’s GLP-1 market is estimated at USD 2.7 billion, while more than 16.5 million adults in the country live with diabetes.
- The launch reinforces Adalvo’s position as a leading development partner in the fast-evolving GLP-1 space
Zug, Switzerland, 9 November 2026 – Adalvo today confirms the launch of Owozy™ (semaglutide solution for injection) by Sandoz in Brazil, bringing a new high-quality treatment option to adults with insufficiently controlled type-2 diabetes in one of the world’s largest and fastest-growing GLP-1 markets.¹
Developed by Adalvo, Owozy™ was approved by the Agência Nacional de Vigilância Sanitária (ANVISA) in July 2026. The product will be commercialised in Brazil by local partner Biolab & Co. under a distribution and promotion agreement signed earlier this year. It is available in a multi-dose disposable pre-filled pen designed to support convenient use by patients and healthcare professionals.
The launch is a significant milestone in Adalvo’s GLP-1 strategy and demonstrates the company’s ability to advance complex medicines from development and regulatory approval through to commercial launch in major global markets.
“This launch is an important milestone for Adalvo and a clear demonstration of our GLP-1 capabilities. Together with Sandoz, we are bringing an Adalvo-developed semaglutide treatment option to patients in a strategically important market. It strengthens our position as a leading development partner in GLP-1s and reflects our ability to turn scientific expertise and strong partnerships into tangible patient access.”
More than 16.5 million adults in Brazil live with diabetes, and approximately one in three remain undiagnosed, representing more than five million people.² The size of this unmet need reinforces the importance of expanding access to effective and accessible diabetes treatments.
Owozy™ is among the earliest new semaglutide treatment options available in Brazil, where the GLP-1 market is valued at an estimated USD 2.7 billion.³ For Sandoz, it is the company’s first semaglutide launch and supports its ambition to become a leading player in the generic GLP-1 market.
References
1. Data on file. Based on IQVIA forecast link data, MAT06 2026.
2. International Diabetes Federation. Brazil: Diabetes country report 2000–2050. Available at: https://diabetesatlas.org/data-by-location/country/brazil/ [Last accessed: November 2026].
3. Data on file. Based on IQVIA analytics link data, MAT 09 2026.
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.